The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Metformin attenuates ovarian cancer cell growth in an AMP‐kinase dispensable manner
Open accessAbstract
Metformin, the most widely used drug for type 2 diabetes activates 59 adenosine monophosphate (AMP)‐activated protein kinase (AMPK), which regulates cellular energy metabolism. Here, we report that ovarian cell lines VOSE, A2780, CP70, C200, OV202, OVCAR3, SKOV3ip, PE01 and PE04 predominantly express ‐α 1 , ‐β 1 , ‐γ 1 and ‐γ 2 isoforms of AMPK subunits. Our studies show that metformin treatment (1) significantly inhibited proliferation of diverse chemo‐responsive and ‐resistant ovarian cancer cell lines (A2780, CP70, C200, OV202, OVCAR3, SKVO3ip, PE01 and PE04), (2) caused cell cycle arrest accompanied by decreased cyclin D1 and increased p21 protein expression, (3) activated AMPK in various ovarian cancer cell lines as evident from increased phosphorylation of AMPKα and its downstream substrate; acetyl co‐carboxylase (ACC) and enhanced β‐oxidation of fatty acid and (4) attenuated mTOR‐S6RP phosphorylation, inhibited protein translational and lipid biosynthetic pathways, thus implicating metformin as a growth inhibitor of ovarian cancer cells. We also show that metformin‐mediated effect on AMPK is dependent on liver kinase B1 (LKB1) as it failed to activate AMPK‐ACC pathway and cell cycle arrest in LKB1 null mouse embryo fibroblasts (mefs). This observation was further supported by using siRNA approach to down‐regulate LKB1 in ovarian cancer cells. In contrast, met formin inhibited cell proliferation in both wild‐type and AMPKα 1/2 null mefs as well as in AMPK silenced ovarian cancer cells. Collectively, these results provide evidence on the role of metformin as an anti‐proliferative therapeutic that can act through both AMPK‐dependent as well as AMPK‐independent pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1
Lizcano, J. M., Göransson, O., Toth, R., Deak, M., Morrice, N. A., Boudeau, J., Hawley, S. A., Udd, L., Mäkelä, T. P., Hardie, D. G., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600110 · Cited by 1,381
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
AMPK, the metabolic syndrome and cancer
Luo, Z., Saha, A. K., Xiang, X., & Ruderman, N. B. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.011 · Cited by 426
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth
Algire, C., Zakikhani, M., Blouin, M.-J., Shuai, J. H., & Pollak, M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0038 · Cited by 185
Research works printed but not linked: 36
- 10.3322/canjclin.55.1.10 · DOI · Paper page
- 10.3322/CA.2007.0010 · DOI · Paper page
- 10.1007/s00018-007-7080-4 · DOI · Paper page
- 10.1158/1940-6207.CAPR-08-0081 · DOI · Paper page
- 10.1016/j.ygyno.2008.04.008 · DOI · Paper page
- 10.1158/0008-5472.CAN-09-0418 · DOI · Paper page
- 10.1136/gut.51.suppl_5.v21 · doi:10.1136/gut.51.suppl_5.v21
- 10.1146/annurev.pharmtox.47.120505.105304 · DOI · Paper page
- 10.1038/ijo.2008.116 · DOI · Paper page
- 10.1007/s00018-008-8244-6 · DOI · Paper page
- 10.1113/jphysiol.2006.108324 · DOI · Paper page
- 10.1074/jbc.M507443200 · DOI · Paper page
- 10.1006/excr.1997.3861 · DOI
- 10.1046/j.1471-4159.1998.71010078.x · DOI
- 10.1111/j.1471-4159.2008.05279.x · DOI
- 10.1111/j.1748-1716.2009.01973.x · DOI
- 10.1016/S0960-9822(02)01077-1 · DOI · Paper page
- 10.1249/01.mss.0000233796.16411.13 · DOI
- 10.1016/S1097-2765(02)00568-3 · DOI · Paper page
- 10.1002/j.1460-2075.1990.tb07420.x · DOI · Paper page
- 10.1111/j.1432-1033.1988.tb14201.x · DOI · Paper page
- 10.1038/sj.onc.1207721 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-2310 · DOI · Paper page
- 10.1158/0008-5472.CAN-08-2641 · DOI
- 10.1074/jbc.M610101200 · DOI
- 10.1016/j.molcel.2005.03.027 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-4447 · DOI · Paper page
- Debernardis D, 1997, p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel, Cancer Res, 57, 870
- Yu D, 1993, Enhanced c‐erbB‐2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A, Cancer Res, 53, 891
- 10.1128/MCB.01621-07 · DOI
- 10.1074/jbc.M009953200 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-0762 · DOI
- 10.1158/0008-5472.CAN-06-0999 · DOI
- 10.1093/hmg/11.13.1497 · DOI · Paper page
- 10.1016/S0899-9007(99)00266-X · DOI · Paper page
- 10.1158/1055-9965.EPI-08-0871 · DOI
Cited by
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493
Rattan, R., Graham, R. P., Maguire, J. L., Giri, S., & Shridhar, V. (2011) · Neoplasia · doi:10.1593/neo.11148 · Cited by 316
Self-citationShi, W.-Y., Xiao, D., Wang, L., Dong, L.-H., Yan, Z.-X., Shen, Z.-X., Chen, S.-J., Chen, Y., & Zhao, W.-L. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.13 · Cited by 308
Metformin inhibits melanoma development through autophagy and apoptosis mechanisms
Tomic, T., Botton, T., Cerezo, M., Robert, G., Luciano, F., Puissant, A., Gounon, P., Allegra, M., Bertolotto, C., Bereder, J.-M., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.86 · Cited by 301
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection
Cohen, D. H., & LeRoith, D. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-11-0374 · Cited by 301
Metadata
- Authors
- Rattan, R., Giri, S., Hartmann, L. C., & Shridhar, V.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2011-01
- Volume
- 15
- Issue
- 1
- Pages
- 166-178
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- OpenAlex
- W2013374433
- Cited by
- 223
- References
- 8
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin attenuates ovarian cancer cell growth in an AMP‐kinase dispensable manner. https://app.cochat.ai/papers/10.1111/j.1582-4934.2009.00954.x
- The paper
- Rattan, R., Giri, S., Hartmann, L. C., & Shridhar, V. (2011). Metformin attenuates ovarian cancer cell growth in an AMP‐kinase dispensable manner. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2009.00954.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.